The combined use of OSMI-4 (another OGT inhibitor) and PD-L1 mAb can restore tumor immunity and synergistically inhibit the growth of liver cancer and melanoma in fully immunized mice, providing new ideas for PD-L1 mediated ICI therapy 9. This evidence concerns the gene CD274 and liver cancer.